Novo Nordisk

Novo Nordisk

Novo NordiskNovo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Novo Nordisk RSS Channel

Filters
List of articles in category Novo Nordisk
Title Published Date
Novo Nordisk and Combine in research collaboration for the treatment of autoimmune diseases 08 January 2010
EFSD/Novo Nordisk partnership for diabetes research in Europe 13 November 2009
Novo Nordisk increased operating profit by 30% in the first nine months of 2009 30 October 2009
The Lancet publishes direct comparison study between liraglutide and exenatide 11 June 2009
Novo Nordisk and VLST Corporation announce collaboration agreement 17 December 2008
Urgent need for social and psychological support for young people with diabetes 10 November 2008
Novo Nordisk acquires intellectual property rights from Neose Technologies 18 September 2008
Build the future of health through collaboration & innovation